Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans

Anesthesiology

Volumn 102, Issue 2, 2005, Pages 409-415

  Dembo, Gregory ^a   Park, Sang B ^a   Kharasch, Evan D ^a,b  

^a Department of Anesthesiology ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; ROFECOXIB; VALDECOXIB;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 13244283391     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200502000-00026     Document Type: Article

References (40)

1. Wu CL, Berenholtz SM, Pronovost PJ, Fleisher LA: Systematic review and analysis of postdischarge symptoms after outpatient surgery. ANESTHESIOLOGY 2002; 96:994-1003
2. Gilron I, Milne B, Hong M: Cyclooxygenase-2 inhibitors in postoperative pain management: Current evidence and future directions. ANESTHESIOLOGY 2003; 99:1198-208
3. Gajraj NM: Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96:1720-38
4. Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg 2003; 97:35-8
5. Rømsing J, Møiniche S: A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand 2004; 48:525-46
6. Kharasch ED: Perioperative COX-2 inhibitors: Knowledge and challenges. Anesth Analg 2004; 98:1-3
7. Munglani R, Fleming BG, Hunt SP: Remembrance of times past: The significance of c-fos in pain. Br J Anaesth 1996; 76:1-4
8. Woolf CJ: Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140:441-51
9. Woolf CJ, Chong MS: Preemptive analgesia: Treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362-79
10. Woolf CJ, Salter MW: Neuronal plasticity: Increasing the gain in pain. Science 2000; 288:1765-9
11. Dirks J, Moiniche S, Hilsted KL, Dahl JB: Mechanisms of postoperative pain: Clinical indications for a contribution of central neuronal sensitization. ANESTHESIOLOGY 2002; 97:1591-6
12. Samad TA, Sapirstein A, Woolf CJ: Prostanoids and pain: Unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002; 8:390-6
13. Svensson CI, Yaksh TL: The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002; 42:553-83
14. 2 release by flurbiprofen enantiomers: A microdialysis study. J Neurochem 2000; 74:2094-100
15. Yaksh TL, Ding DM, Conway CM, Svensson C, Luo ZD, Isakson PC: The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21:5847-53
16. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ: Interleukin-1β-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410:471-5
17. 2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 2002; 87:2851-7
18. McCrory C, Fitzgerald D: Spinal prostaglandin formation and pain perception following thoracotomy: A role for cyclooxygenase-2. Chest 2004; 125:1321-7
19. Ghilardi JR, Svensson CI, Rogers SD, Yaksh TL, Mantyh PW: Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci 2004; 24:2727-32
20. 2 release in the spinal cord. J Neurochem 2001; 79:777-86
21. Buvanendran A, Kroin JS, Tuman KJ, Lubenow TR, Elmofty D, Moric M, Rosenberg AG: Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: A randomized controlled trial. JAMA 2003; 290:2411-8
22. Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease: A double-edged sword. Neuron 2002; 35:419-32
23. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P: Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets 2003; 4:461-8
24. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003; 100:5473-8
25. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL: Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 2004; 1007:98-108
26. Nathoo N, Barnett GH, Golubic M: The eicosanoid cascade: Possible role in gliomas and meningiomas. J Clin Pathol 2004; 57:6-13
27. Morrison BW, Fricke J, Brown J, Yuan W, Kotey P, Mehlisch D: The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. J Am Dent Assoc 2000; 131:1729-37
28. Depre M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ: Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56:167-74
29. Clemett D, Goa KL: Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59:957-80
30. Ormrod D, Wellington K, Wagstaff AJ: Valdecoxib. Drugs 2002; 62:2059-71
31. Davies NM, Teng XW, Skjodt NM: Pharmacokinetics of rofecoxib: A specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42:545-56
32. Hawkey CJ: COX-2 inhibitors. Lancet 1999; 353:307-14
33. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-7
34. Feng MR: Assessment of blood-brain barrier penetration: In silico, in vitro and in vivo. Curr Drug Metab 2002; 3:647-57
35. Brune K, Hinz B: Selective cyclooxygenase-2 inhibitors: Similarities and differences. Scand J Rheumatol 2004; 33:1-6
36. Lee G, Dallas S, Hong M, Bendayan R: Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53:569-6
37. Graff CL, Pollack GM: Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 2004; 5:95-108
38. Martin I: Prediction of blood-brain barrier penetration: Are we missing the point? Drug Discov Today 2004; 9:161-2
39. de Lange EC, Danhof M: Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clin Pharmacokinet 2002; 41:691-703
40. Higuchi H, Hirata J, Adachi Y, Kazama T: Influence of lumbosacral cerebrospinal fluid density, velocity, and volume on extent and duration of plain bupivacaine spinal anesthesia. ANESTHESIOLOGY 2004; 100:106-14